TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36286885
Drug: Dietressa (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietressa (6 tablets per day for 24 weeks)
Study: 33301386
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal daily routine)
Study: 33428746
Drug: CrashCourse (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrashCourse (CC)
Study: 35212274
Drug: GSMs-TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSMs-TACE plus synchronous antigen-presenting dendritic cell (DC) sequential reinfusion
Study: 36151584
Drug: Perinatal Emotional
Normalized name: PERINEAL WASH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perinatal Emotional Skills Groups (ESGs) + Treatment as Usual (TAU)
Study: 34802026
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (tTXA) 1g (20mL) soaked in absorbable gelatin sponge
Study: 34802026
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (tTXA)
Study: 32701903
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg/d)
Study: 32215767
Drug: Debridement and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement and laser treatment
Study: 33753147
Drug: Baicalein tablets
Normalized name: Baicalein
DrugBank: Baicalein (DB16101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baicalein tablets (200 mg, 400 mg, 600 mg, or 800 mg)
Study: 33753147
Drug: Baicalein tablets
Normalized name: Baicalein
DrugBank: Baicalein (DB16101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baicalein tablets (400 mg)
Study: 33753147
Drug: Baicalein tablets
Normalized name: Baicalein
DrugBank: Baicalein (DB16101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baicalein tablets (600 mg)
Study: 36969889
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg TDF
Study: 33789011
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg upadacitinib
Study: 33789011
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg upadacitinib vs. Adalimumab
Study: 34727201
Drug: L-carnitine 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 1000 mg/day
Study: 34859631
Drug: Routine outpatient
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine outpatient treatment
Study: 36494006
Drug: Chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or vinflunine)
Study: 83012907
Drug: Methadone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 20 mg
Study: 35676012
Drug: Biodegradable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodegradable polymer drug-eluting stents (BP-DES)
Study: 32580620
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (1200 mg) + Faradic (three 1 hour sessions) + weight loss regime
Study: 32580620
Drug: Placebo (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1200 mg) + weight loss regime
Study: 33631337
Drug: Preoperative calcium
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative calcium and calcitriol supplementation (calcitriol 0.25 μg po bid and calcium carbonate 1,500 mg po tid 5 days preoperatively and continued postoperatively)
Study: 34002565
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (vitamin E capsules, coenzyme Q10 capsules, Wuzi Yanzong pills)
Study: 32692994
Drug: Blood arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood arsenic levels less than 3.69 μg/L
Study: 35186258
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 3-monthly (PP3M)
Study: 33535835
Drug: Fluzoparib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib (120 mg) under fed conditions
Study: 33535835
Drug: Fluzoparib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib (120 mg) under fasted conditions
Study: 32410362
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral MTX and OMP dexamethasone
Study: 33904625
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g CG per day
Study: 33904625
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g CG per day
Study: 34625316
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (received the core and up to 4 custom elements of treatment, wrote what each image displayed)
Study: 34063790
Drug: Minor allele
Normalized name: Vinca minor extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minor allele frequencies of SNPs associated with vitamin A metabolism
Study: 35568683
Drug: LDL-C 190-219
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C 190-219 mg/dL
Study: 35568683
Drug: LDL-C 220-249
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C 220-249 mg/dL
Study: 35568683
Drug: LDL-C ≥300
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C ≥300 mg/dL
Study: 34176407
Drug: Baricitinib therapy
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib therapy
Study: 34197452
Drug: Pharmaceutical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical and healthy lifestyle interventions
Study: 33749970
Drug: Ideal Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ideal Body Weight (IBW) dosing
Study: 33749970
Drug: Total Body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Body Weight (TBW) dosing
Study: 38262066
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg daily)
Study: 33142495
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 at 2,760 IU/kg plus 25OHD at 2,760 IU (69 μg)/kg
Study: 35380078
Drug: Continuous siponimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous siponimod 2 mg/day
Study: 34755994
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of normal saline 0.9% as irrigation solution (Group A)
Study: 34755994
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of normal saline 0.9% as irrigation solution (Group B)
Study: 34755994
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml of normal saline 0.9% as irrigation solution (Group C)
Study: 32956446
Drug: 23-month ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 23-month ticagrelor monotherapy following 1-month dual anti-platelet therapy (DAPT)
Study: 32956446
Drug: 23-month ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 23-month ticagrelor monotherapy following 1-month DAPT
Study: 35527411
Drug: Adaptive biofeedback
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive biofeedback training combined with oral administration of compound polyethylene glycol 4000-electrolyte powder
Study: 35527411
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of compound polyethylene glycol 4000-electrolyte powder alone
Study: 34517840
Drug: Dexmedetomidine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.25 µg/mL)
Study: 35342437
Drug: Olibanum extract
Normalized name: Origanum majorana extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olibanum extract orally disintegrating tablets (ODT), 4 times a day for 3 days
Study: 35342437
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally disintegrating tablets (ODT), 4 times a day for 3 days
Study: 33208831
Drug: morphine (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (0.08 mg/kg) after forced awakening (FA)
Study: 33208831
Drug: morphine after
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine after forced awakening (FA) in females
Study: 35012992
Drug: Superficial cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial cervical plexus block (20 mL of 0.5% ropivacaine)
Study: 35531757
Drug: Tramadol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (2 mg/kg)
Study: 32569281
Drug: Iron intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron intake less than 180 tablets
Study: 32034028
Drug: Luseogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin 2.5 mg once daily for 8 weeks
Study: 36404985
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum in addition to standard therapy
Study: 36404985
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Ondansetron 4 mg IV intra-operatively)
Study: 32359936
Drug: Nanoemulsion eye
Normalized name: ANA-conjugated dactinomycin nanoemulsion
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanoemulsion eye drop (used for 1 month, four times daily)
Study: 32078353
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inreach and outreach
Study: 32343960
Drug: JNJ-6379 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-6379 (25 mg, 75 mg, 150 mg, or 250 mg daily for 4 weeks)
Study: 32343960
Drug: JNJ-6379 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-6379 (any dose)
Study: 32343960
Drug: JNJ-6379 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-6379 (150 mg)
Study: 35263680
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day ifenprodil tartrate for 4 weeks
Study: 33298117
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of the Insight Timer meditation app for 10 minutes daily for 30 days
Study: 35121137
Drug: Two additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two additional intensive oral hygiene appointments before and after GA
Study: 36199780
Drug: Hormone group
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone group (prednisone acetate, n = 34)
Study: 36199780
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (Ginkgo‐Damole combined with prednisone acetate, n = 30)
Study: 38326432
Drug: Diphenhydramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg)
Study: 32311398
Drug: PF-06700841 100
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 100 mg once weekly
Study: 37844838
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose administration
Study: 37844838
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose administration
Study: 35852274
Drug: 20-mL buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mL buffered 1% lidocaine paracervical block
Study: 35852274
Drug: 40-mL buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mL buffered 0.5% lidocaine paracervical block
Study: 35852274
Drug: 40-mL buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mL buffered 0.5% lidocaine paracervical block (induced abortion)
Study: 35852274
Drug: 20-mL buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mL buffered 1% lidocaine paracervical block (induced abortion)
Study: 35852274
Drug: 20-mL buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mL buffered 1% lidocaine paracervical block (pain during administration)
Study: 35852274
Drug: 40-mL buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mL buffered 0.5% lidocaine paracervical block (pain during administration)
Study: 33081705
Drug: Medication placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication placebo
Study: 35803368
Drug: Target-Controlled Infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-Controlled Infusion (TCI) of propofol (effect-site, 2 μg.mL−1 plus 0.5 μg.mL−1 until unconsciousness and as necessary for agitation)
Study: 35803368
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus of propofol (1 mg.kg−1 plus 0.5 mg.kg−1 every 5 minutes or as necessary)
Study: 32900329
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg 12-hourly
Study: 32731829
Drug: Incisional negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative-pressure wound therapy (iNPWT)
Study: 32331049
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg SPN-812 (supratherapeutic dose)
Study: 35000914
Drug: HEP+CWHi (Constant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEP+CWHi (Constant Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 100% duty cycle, 1.0 W/cm2)
Study: 35000914
Drug: HEP+PWLi (Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEP+PWLi (Low Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 50% duty cycle, 0.5 W/cm2)
Study: 35000914
Drug: HEP+CWLi (Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEP+CWLi (Low Intensity Ultrasound, 10% hydrocortisone gel, 10 minutes, 1.0 MHz, 100% duty cycle, 0.5 W/cm2)
Study: 32522156
Drug: LOR (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOR (group L)
Study: 36117007
Drug: Arthrocentesis as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis as initial treatment
Study: 33632925
Drug: Nivolumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab with ipilimumab and two cycles of platinum-doublet chemotherapy
Study: 32223044
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose EPC (140 mg EPC and 130 mg OPC)
Study: 32223044
Drug: OPC (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC (6 mg EPC and 130 mg OPC)
Study: 32950416
Drug: Litos drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litos drug-coated balloon (DCB)
Study: 34263700
Drug: Infliximab added
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab added to DMARD combination
Study: 34263700
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to DMARD combination
Study: 33469270
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (OcalivaTM) under fasting conditions
Study: 33469270
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (OcalivaTM) under fed conditions
Study: 33469270
Drug: Food intake
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food intake effect on pharmacokinetics
Study: 34325772
Drug: Tinidazole 200
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 200 mg/kg PO (single dose)
Study: 32076124
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment
Study: 32347785
Drug: Licensed trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed trivalent influenza vaccines (TIVs)
Study: 32928709
Drug: Alirocumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 300 mg Q4W
Study: 34037351
Drug: Ethylmethylhydroxypyridine succinate
Normalized name: succinate
DrugBank: Emoxypine (DB19172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethylmethylhydroxypyridine succinate (Neurox) 1 tablet (125 mg) 3 times a day for 4 weeks
Study: 35037963
Drug: BCG (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (once weekly for 6 weeks plus subsequent maintenance)
Study: 33726834
Drug: GSK2982772 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 60 mg orally 2 or 3 times daily for 84 days
Study: 33726834
Drug: GSK2982772 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 60 mg
Study: 37169401
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for 4 weeks
Study: 35696054
Drug: RIV‐TDS Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIV‐TDS Test Product (transdermal patch formulation of Rivastigmine with a release rate of 13.3 mg/24 h)
Study: 35696054
Drug: Exelon Marketed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exelon Marketed Reference Product (transdermal patch formulation of Rivastigmine with a release rate of 13.3 mg/24 h)
Study: 32926604
Drug: Dasotraline (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline (4, 6, or 8 mg/d)
Study: 35485182
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (Haizheng Pharmaceutical Group)
Study: 35485182
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (AstraZeneca Pharmaceuticals LP)
Study: 36271849
Drug: RCF 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCF 75 mg once daily (QD)
Study: 36271849
Drug: RCF (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCF (both doses)
Study: 35613823
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (pain control with analgesics, physical therapy, and osteoporosis medication)
Study: 33467951
Drug: Mouthwashes (teas,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwashes (teas, supplements, oil applications)
Study: 33637332
Drug: Tegoprazan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (100 mg/d) with triple-antibiotic therapy (1500 mg/d metronidazole, 2000 mg/d tetracycline, and 1200 mg/d bismuth) for 7 days
Study: 33637332
Drug: Triple-antibiotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-antibiotic therapy (1500 mg/d metronidazole, 2000 mg/d tetracycline, and 1200 mg/d bismuth) with tegoprazan for 7 days
Study: 32639369
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (informed it may be a local anaesthetic cream)
Study: 32639369
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (informed the cream was inactive)
Study: 33004536
Drug: Abituzumab 1500
Normalized name: sacituzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abituzumab 1500 mg
Study: 33004536
Drug: Abituzumab 500
Normalized name: sacituzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abituzumab 500 mg
Study: 39104653
Drug: Abrocitinib 100
Normalized name: abrocitinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrocitinib 100 mg
Study: 32340820
Drug: Ketamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (4 mg/kg IM or 1 mg/kg IV)
Study: 32340820
Drug: Haloperidol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5-10 mg IM or IV) + Lorazepam (1-2 mg IM or IV)
Study: 36323602
Drug: Sublingual melatonin
Normalized name: Melatonin/Pyridoxine 2.5 MG-0.338 MG Sublingual Tablet [BASIC'S SUBLINGUAL MELATONIN WITH B6]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual melatonin 3 mg
Study: 36281107
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no treatment
Study: 33612485
Drug: Epinephrine plus
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine plus vasopressin (0.1 mL per kg vasopressin, 0.1 mL per kg epinephrine 1:10000)
Study: 35837022
Drug: Phenylephrine 70,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 70, 80, 90, 100, and 110 μg for normotension
Study: 35346389
Drug: Kinesiology tape,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesiology tape, elevation and massage (Trial Treatment - TT)
Study: 35346389
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (compression, elevation and massage - TAU)
Study: 37985968
Drug: eptinezumab 300
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: eptinezumab 300 mg
Study: 34551130
Drug: eptinezumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: eptinezumab (both doses)
Study: 33035700
Drug: IND/GLY/MF 150/50/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/GLY/MF 150/50/160 μg
Study: 34009141
Drug: Bicarbonate treatment
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate treatment
Study: 32903368
Drug: Psychological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapy
Study: 32568096
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg loading dose)
Study: 35224090
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy alone (non-CPM group)
Study: 35618629
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy plus radiotherapy with pembrolizumab plus olaparib (Group B)
Study: 35618629
Drug: Durvalumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab monotherapy (Group C)
Study: 36763359
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser therapy (SLT)
Study: 35264432
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg or Baricitinib 4 mg + MTX